Protocol No.: OCR13966
Sponsor Protocol No.: BEATAML
Beat AML: Personalized Medicine for Acute Myeloid Leukemia Based on Functional Genomics
In this study, DNA sequencing, computational biology modeling, and ex vivo drug sensitivity assays will be utilized to define clinically relevant gene mutations and identify potential therapeutics for patients with acute myeloid leukemia (AML).
Age Group: Adult
1. Individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
2. Age between 18 and 80 years of age
Applicable Disease Sites
View study listing on ClinicialTrials.gov